Abstract |
Protein kinase C (PKC) belongs to the serine and threonine kinase family. At least ten PKC isoforms have been identified and subdivided into three groups: classical (alpha, beta I, beta II and gamma), novel (delta, epsilon, theta and eta), and atypical (zeta and iota/lambda). Two calcium-insensitive isoforms of novel PKC, PKC delta and epsilon, have received particular attention as promising targets for new drugs. PKCs play a multifaceted role in cellular responses in a range of tissues. Professor Mochly-Rosen's group and KAI Pharmaceuticals Inc. have developed drugs targeted against PKC delta (KAI-9803) and epsilon (KAI-1678). These drugs ameliorate pathological conditions in acute myocardial infarction and reduce pain via specific modulation of membrane-translocation of PKC delta or epsilon. Another research group has recently used the KinAce() approach to produce PKC epsilon-abrogating peptides (KCe-12 and KCe-16) that are based on the catalytic domain of PKC. These peptides specifically inhibit PKC epsilon and ameliorate pathological conditions in a rodent insulin resistance model. This review describes the development of these therapeutic drugs targeting PKC delta and epsilon by two independent groups in the light of recent patents.
|
Authors | Tomo Yonezawa, Riho Kurata, Minoru Kimura, Hidetoshi Inoko |
Journal | Recent patents on DNA & gene sequences
(Recent Pat DNA Gene Seq)
Vol. 3
Issue 2
Pg. 96-101
( 2009)
ISSN: 2212-3431 [Electronic] United Arab Emirates |
PMID | 19519579
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Enzyme Inhibitors
- KAI 9803
- KAI-1678
- Peptides
- Protein Kinase C-delta
- Protein Kinase C-epsilon
|
Topics |
- Animals
- Enzyme Inhibitors
(therapeutic use)
- Gene Targeting
- Humans
- Patents as Topic
- Peptides
(therapeutic use)
- Protein Kinase C-delta
(antagonists & inhibitors, genetics, metabolism)
- Protein Kinase C-epsilon
(antagonists & inhibitors, genetics, metabolism)
|